NGS (FoundationOne Liquid Dx, Cambridge, MA, USA) identified genomic alterations, including ROS1, EP300, TERT, and TP53, revealing that the tumor harbored an EZR-ROS1 rearrangement (Figure 3). Here, ROS1 is linked to neoplasm.